ID   L2-2GC
AC   CVCL_W602
SY   IM2GC; MPIi003-A-1
DR   BioSamples; SAMEA104383130
DR   hPSCreg; MPIi003-A-1
DR   SKIP; SKIP000301
DR   Wikidata; Q54900989
RX   PubMed=23472874;
CC   From: Max Planck Institute for Molecular Biomedicine; Munster; Germany.
CC   Characteristics: The heterozygous LRRK2 p.Gly2019Ser (c.6055G>A) mutation of the donor has been corrected by ZFN.
DI   NCIt; C26845; Parkinson's disease
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_W603 ! L2-2Mut
SX   Female
AG   80-82Y
CA   Induced pluripotent stem cell
DT   Created: 16-04-14; Last updated: 25-02-19; Version: 5
//
RX   PubMed=23472874; DOI=10.1016/j.stem.2013.01.008;
RA   Reinhardt P., Schmid B., Burbulla L.F., Schondorf D.C., Wagner L.,
RA   Glatza M., Hoing S., Hargus G., Heck S.A., Dhingra A., Wu G.,
RA   Muller S., Brockmann K., Kluba T., Maisel M., Kruger R., Berg D.,
RA   Tsytsyura Y., Thiel C.S., Psathaki O.E., Klingauf J., Kuhlmann T.,
RA   Klewin M., Muller H., Gasser T., Scholer H.R., Sterneckert J.;
RT   "Genetic correction of a LRRK2 mutation in human iPSCs links
RT   parkinsonian neurodegeneration to ERK-dependent changes in gene
RT   expression.";
RL   Cell Stem Cell 12:354-367(2013).
//